Login / Signup

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.

Josephine M N Lopes CardozoCaroline A DrukkerEmiel J T RutgersMarjanka K SchmidtAnnuska M GlasAnke WitteveenFatima CardosoMartine J PiccartLaura J EssermanCoralie PoncetLaura van 't Veer
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.
Keyphrases